Cargando…
Effects of a novel nutraceutical combination (BruMeChol™) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial
BACKGROUND: Elevated cholesterol levels and systemic inflammation are considered relevant risk factors for cardiovascular disease (CVD) development and progression. Increasing evidence suggests that cholesterol-lowering and inflammation-lowering nutraceuticals are useful in the management of moderat...
Autores principales: | Bonfigli, Anna Rita, Protic, Olga, Olivieri, Fabiola, Montesanto, Alberto, Malatesta, Gelsomina, Di Pillo, Raffaele, Antonicelli, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336431/ https://www.ncbi.nlm.nih.gov/pubmed/32631422 http://dx.doi.org/10.1186/s13063-020-04551-4 |
Ejemplares similares
-
Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of a Nutraceutical Combination Monacolin K-Free on the Lipid and Inflammatory Profile of Subjects with Hypercholesterolemia
por: Protic, Olga, et al.
Publicado: (2022) -
Nutraceutical Combinations in Hypercholesterolemia: Evidence from Randomized, Placebo-Controlled Clinical Trials
por: Protic, Olga, et al.
Publicado: (2021) -
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Galeazzi, Roberta, et al.
Publicado: (2018) -
Ions Bru
Publicado: (1994) -
The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents
por: Giuliani, Angelica, et al.
Publicado: (2022)